VIDA Partners with Riverain Technologies to Enhance AI Imaging Solutions in Life Sciences
Chicago, Nov. 30, 2025 — VIDA Diagnostics, Inc., a leading name in clinical imaging intelligence, has announced a strategic collaboration with Riverain Technologies during the Radiologic Society of North America (RSNA) meeting. This partnership aims to incorporate Riverain’s ClearRead™ CT cardiothoracic AI analysis suite into the VIDA Intelligence Platform, a cutting-edge imaging management system that ensures the delivery of high-quality biomarker data and operational efficiency on a global scale.
The integration of Riverain into the VIDA ecosystem builds on existing relationships with prominent AI partners, including Thirona and National Jewish Health. By consolidating access to these advanced technologies through the VIDA Intelligence Platform, pharmaceutical research teams gain comprehensive imaging biomarker services, streamlining vendor management and standardizing outputs. This move capitalizes on a secure infrastructure already utilized by thousands of clinical trial sites worldwide.
Susan Wood, PhD, President and CEO of VIDA, emphasized the necessity for deeper insights in therapeutic understanding and patient evaluation, particularly regarding diseases such as COPD, cardiovascular disease, and lung cancer, which impact millions globally. “Our collaboration with Riverain equips pharmaceutical sponsors with essential imaging tools to advance next-generation therapies,” she stated.
Steve Worrell, CEO of Riverain Technologies, expressed enthusiasm for extending their ClearRead AI technology to VIDA’s platform, enhancing its clinical trial solutions for the expanding life sciences sector. This partnership specifically addresses the significant health challenge posed by the “Big Three” chest diseases—Cardiovascular Disease (CVD), Respiratory issues/COPD, and Lung Cancer—collectively responsible for 40% of annual global deaths.
Moreover, the ClearRead CT technology employs sophisticated AI algorithms that deliver critical metrics related to pulmonary nodules, coronary artery calcification (CAC), and hypodense lung tissue. The ability to quantify these biomarkers is an invaluable asset in diagnosing and treating prevalent chest diseases.
About VIDA: VIDA is dedicated to advancing the approval and adoption of life-saving therapies through AI-driven imaging solutions. The VIDA Intelligence Platform empowers biopharma sponsors with scalable quantitative imaging capabilities, also supporting OSIC Cloud, the world’s largest ILD imaging repository. For more information, visit https://vidalung.ai.
About Riverain: Riverain Technologies is focused on enhancing the field of radiology by optimizing cardiothoracic diagnostics. The company is committed to innovation, improving outcome accuracy, and transforming diagnostic workflows within healthcare. For further details, visit https://www.riveraintech.com.
